{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-056278","form_type":"8-K","ticker":"OGN","cik":"0001821825","company_name":"Organon & Co.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.521323+00:00","generated_at":"2026-06-25T23:57:34.902549+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Organon Q1 revenue $1.567B (+8% ex-FX); adj. EPS $1.65; reaffirms FY guidance","bullets":["Revenue $1,567M, +4% as-reported / +8% ex-FX vs Q1 2021; Women's Health -5%, Biosimilars +22%, Established Brands +10%.","Net income from cont. ops $348M ($1.36 diluted EPS); adjusted net income $420M ($1.65 adj. diluted EPS).","Adjusted EBITDA $647M; gross margin 64.2% (adj. 66.5%); board declares $0.28 quarterly dividend.","Full year 2022 financial guidance reaffirmed; acquired rights to Marvelon/Mercilon and Xaciato license in certain markets."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-056278","json":"https://secwatch.observer/filing/0001104659-22-056278.json","markdown":"https://secwatch.observer/filing/0001104659-22-056278.md","text":"https://secwatch.observer/filing/0001104659-22-056278.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821825/000110465922056278/0001104659-22-056278-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821825/000110465922056278/tm2214364d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:57:34.902549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}